Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 60
Healthy Volunteers: t
View:

• Inclusion Criteria for participants with adult-onset HD:

• Age of 25-60 years.

• Genetically confirmed HD (HD-ISS Stage 2 or early Stage 3)

• English speaking.

• Age of 25-60 years.

• English speaking.

• Self-identified support person or family member of the enrolled participants with HD.

• 18 years or older

• English speaking.

Locations
United States
New York
University of Rochester Medical Center
RECRUITING
Rochester
Contact Information
Primary
Sugitha Maheswaran, BS
Sugi.Mahes@chet.rochester.edu
5857040344
Time Frame
Start Date: 2025-06-20
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 100
Treatments
20 HD-ISS Stage 2
(CAG ≥ 40 and sign/symptom of HD) with or without a support person or family member
20 HD-ISS early Stage 3
(CAG ≥40 and sign symptom and functional impact) with or without a support person or family member
20 Healthy controls
age and sex-matched
Sponsors
Collaborators: Food and Drug Administration (FDA)
Leads: University of Rochester

This content was sourced from clinicaltrials.gov